Evaluate gives you the understanding and time you need to drive better decisions.

When you partner with Evaluate, our constantly expanding solutions and transparent methodologies and datasets are instantly at your disposal, along with expert, personalised support.

Evaluate gives you the time and confidence to turn understanding into insight, and insight into action.

How we can help you
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Market Reports
Market Reports
Thought Leadership

Read our wide range of complimentary market reports covering sector performance and valuation, market trends and global forecasts, including our annual EvaluatePharma World Preview. 

More
EvaluatePharma
OUR PRODUCTS
EvaluatePharma

Get a global view of the pharmaceutical market’s past, present and future performance with consensus forecasts to 2024 and the first single view of the risk and reward of the R&D landscape from EvaluatePharma Vision.

More
custom solutions
OUR SERVICES
Custom Solutions

Improve your strategic decision-making with customised solutions that draw on our team of industry experts and trusted commercial intelligence. 

More
Kickstarting ideas
 Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Thumbnail

Slowly, TG investors start to fear the worst

The company’s stock slides 12% on fears that the goalposts in its all-important Unity-CLL trial are being moved.
Thumbnail

Novartis nears gene therapy confirmation

After buying Avexis for $8.7bn to access a potentially transformative treatment for spinal muscular atrophy, data approaches from Novartis.
Thumbnail

Argenx moves to make the most of its lead

Thumbnail

Tyk2 reaches tipping point

Thumbnail

Teva tries to make something out of nothing with Ajovy approval

Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up